

# LIPOXIN MEDIATED NEUROPROTECTION

Tech ID: 27404 / UC Case 2017-109-0

## PATENT STATUS

Country	Type	Number	Dated	Case
United States Of America	Issued Patent	11,439,615	09/13/2022	2017-109
Canada	Published Application			2017-109

Additional Patent Pending

## BRIEF DESCRIPTION

This is small molecule neuroprotective activity secreted from resting astrocytes in the inner retina, where neighboring retinal ganglion cell neurons (RGCs) are vulnerable to irreversible damage in the neurodegenerative disease glaucoma.

## SUGGESTED USES

Therapeutic treatment with LXB<sub>4</sub> is efficacious in both pathological and functional measures in a chronic glaucoma model. Together, these results indicate a novel resident neuroprotective mechanism for LXB<sub>4</sub> that can become deficient following neuronal injury. Restoration of this balance suggests a therapeutic potential.

## ADVANTAGES

The role and regulation of labile small molecule factors in neuroinflammation and neurodegeneration is not well understood. This small molecule has neuroprotective activity secreted from resting astrocytes in the inner retina, where neighboring retinal ganglion cell neurons (RGCs) are vulnerable to irreversible damage in the neurodegenerative disease glaucoma.

## RELATED MATERIALS

## CONTACT

Craig K. Kennedy  
craig.kennedy@berkeley.edu  
tel: .



## INVENTORS

» Flanagan, John G.

## OTHER INFORMATION

### KEYWORDS

Retinal, Glaucoma

### CATEGORIZED AS

- » **Medical**
- » Disease: Ophthalmology and Optometry

### RELATED CASES

2017-109-0